Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroCHIPS gets new US patent
MicroCHIPS claims that the current patent in combination with US patent no. 7,070,590 offers coverage for the design and fabrication of reservoir-based medical devices used for implantable drug
MicroCHIPS claims that the current patent in combination with US patent no. 7,070,590 offers coverage for the design and fabrication of reservoir-based medical devices used for implantable drug
Valeant is planning to commence a consent solicitation process during the week of April 4th in an effort to replace Cephalon’s current Board of Directors with its own
The Health Sciences Clinical Development Center 3.1 provides integration, increased automation, and expanded data standardization to enable accelerated processing of clinical trial data from multiple sources in a
As per the terms of the agreement, Minophagen is expected to get license for the development and commercialization of Eisai‘s Bexarotene in Japan. However, Eisai is expected to
The double blind, placebo controlled, multi-center clinical study will evaluate the effects of OCA compared with placebo in adult NASH patients. The 72-week study will enroll 280 patients
As per the terms of the agreement, Shionogi is responsible to pay technology access fees and payments to Shionogi for follow-up chemistry for the generation of various, novel
Cinryze is a plasma-derived C1 esterase inhibitor product that has been approved by the US FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with
According to GSK and Valeant, EC has given its approval on the basis of the results from pivotal Phase III studies 1 and 2 and Study 205, a
Under the collaboration agreement, Asterand and 5AM Solutions are expected to share the development costs to build software offering a standardized solution to identify, annotate and distribute human
CTP-499, invented using Concert’s DCE Platform (deuterated chemical entity platform), is a potential first-in-class treatment for chronic kidney disease. It is a deuterium containing new chemical entity which